 CAMBRIDGE, England BOSTON--BUSINESS WIRE--Bicycle Therapeutics plc NASDAQ: BCYC, a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide Bicycle technology, today reported financial results for the fourth quarter and full year ended December 31, 2020 and discussed recent corporate updates. Bicycle has overcome the unprecedented challenges caused by the COVID-19 pandemic this past year, executing on our 2020 goals, inc 